However, most patients with NSCLC do not have these oncogenic drivers, and treatment options are limited to cytotoxic chemotherapy for these patients. Recently, various kinds of immune checkpoint inhibitors (ICIs) have been established for several cancers, targeting PD1, PDL1, and CTLA-4 [5-7]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.